Biological Psychiatry, 38(12), 814-818, 1995
Seven women with histories of puerperal psychosis and four with histories of puerperal major depression were consecutively treated with high-dose oral estrogen immediately following delivery. None of the women had histories of nonpuerperal affective disorder, and all women were affectively well throughout the current pregnancy and at delivery. Despite the high risk for recurrent illness in this population, only one woman developed relapse of postpartum affective disorder. All others remained entirely well and required no treatment with psychotropic medications during the 1 year follow-up period. This low rate of relapse, 9% compared to an expected 35-60% without prophylaxis, suggests that oral estrogen may stem the rapid rate of change in estrogen following delivery, thereby preventing the potential impact on dopaminergic and serotonergic neuroreceptors. It is hypothesized that the rapid rate of change of estrogen after delivery creates an "estrogen withdrawal state." This may be a critical factor in driving acute puerperal affective psychosis and early-onset puerperal major depression.
Sichel, D. A., Cohen, L. S., Robertson, L. M., Ruttenberg, A., & Rosenbaum, J. F. (1995). Prophylactic estrogen in recurrent postpartum affective disorder. *Biological psychiatry*, *38*(12), 814-818. https://doi.org/10.1016/0006-3223(95)00063-1
Sichel DA, Cohen LS, Robertson LM, Ruttenberg A, Rosenbaum JF. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry. 1995;38(12):814-818. doi:10.1016/0006-3223(95)00063-1
Sichel, D. A., et al. "Prophylactic estrogen in recurrent postpartum affective disorder." *Biological psychiatry*, vol. 38, no. 12, 1995, pp. 814-818.
Administration, Oral, Adult, Depression, Postpartum/diagnosis/drug Therapy/psychology, Dose-Response Relationship, Drug, Drug Administration Schedule, Estrogen Replacement Therapy/psychology, Estrogens/administration & Dosage/adverse Effects, Estrogens, Conjugated (USP)/administration & Dosage/adverse Effects, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Personality Inventory, Pilot Projects, Pregnancy, Psychiatric Status Rating Scales, Psychotic Disorders/diagnosis/drug Therapy/psychology, Puerperal Disorders/diagnosis/drug Therapy/psychology, Recurrence, Risk Factors, Estrogens, Estrogens, Conjugated (USP)